| Ocular Hypertension
Rhopressa vs Lumigan
Side-by-side clinical, coverage, and cost comparison for ocular hypertension.Deep comparison between: Rhopressa vs Lumigan with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLumigan has a higher rate of injection site reactions vs Rhopressa based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Lumigan but not Rhopressa, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Rhopressa
Lumigan
At A Glance
Ophthalmic (eye drop)
Once daily (evening)
Rho kinase inhibitor
Ophthalmic
Once daily
Prostaglandin analog
Indications
- Glaucoma, Open-Angle
- Ocular Hypertension
- Glaucoma, Open-Angle
- Ocular Hypertension
Dosing
Glaucoma, Open-Angle, Ocular Hypertension One drop in the affected eye(s) once daily in the evening; when used concomitantly with other topical ophthalmic products to lower IOP, administer each product at least 5 minutes apart.
Glaucoma, Open-Angle; Ocular Hypertension One drop in the affected eye(s) once daily in the evening; if used concomitantly with other topical ophthalmic drugs, administer at least 5 minutes apart.
Contraindications
—
- Hypersensitivity to bimatoprost or any excipient
Adverse Reactions
Most common (>=20%) Conjunctival hyperemia, corneal verticillata, instillation site pain, conjunctival hemorrhage
Common (5-10%) Instillation site erythema, corneal staining, blurred vision, increased lacrimation, erythema of eyelid, reduced visual acuity
Postmarketing Epithelial corneal edema in patients with pre-existing corneal stromal edema or following ocular procedures affecting corneal endothelial function
Most common (>=1%) Conjunctival hyperemia, conjunctival edema, conjunctival hemorrhage, eye irritation, eye pain, eye pruritus, erythema of eyelid, eyelid pruritus, growth of eyelashes, hypertrichosis, instillation site irritation, punctate keratitis, skin hyperpigmentation, blurred vision, reduced visual acuity
Postmarketing Asthma-like symptoms, dizziness, dry eye, dyspnea, eye discharge, eye edema, foreign body sensation, headache, hypersensitivity, hypertension, increased lacrimation, periorbital and lid changes, photophobia
Pharmacology
Netarsudil is a rho kinase inhibitor believed to reduce intraocular pressure by increasing the outflow of aqueous humor through the trabecular meshwork; the exact mechanism is unknown.
Bimatoprost is a prostaglandin analog that lowers intraocular pressure by increasing aqueous humor outflow through both the trabecular meshwork and uveoscleral routes, selectively mimicking naturally occurring prostamides.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Rhopressa
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (6/12) · Qty limit (9/12)
Lumigan
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (1/12) · Qty limit (9/12)
UnitedHealthcare
Rhopressa
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (2/8) · Qty limit (4/8)
Lumigan
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Rhopressa
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (2/3) · Qty limit (1/3)
Lumigan
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Rhopressa.
No savings programs available for Lumigan.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
RhopressaView full Rhopressa profile
LumiganView full Lumigan profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.